Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers

Background: Vicagrel is a novel anti-platelet drug and hydrolyzed to the same intermediate as clopidogrel via esterase, instead of CYP2C19. Here we report the first clinical trial on the tolerability, pharmacokinetics and pharmacodynamics of different doses of vicagrel, and comparison with clopidogr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaojiao, Liu, Cai, Zhu, Xiaoxue, Wei, Haijing, Zhang, Hong, Chen, Hong, Chen, Guiling, Yang, Deming, Sun, Hongbin, Shen, Zhenwei, Zhang, Yifan, Li, Wei, Yang, Jin, Liu, Yongqiang, Lai, Xiaojuan, Gong, Yanchun, Liu, Xuefang, Li, Yongguo, Zhong, Dafang, Niu, Junqi, Liu, Bin, Ding, Yanhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019484/
https://www.ncbi.nlm.nih.gov/pubmed/29973877
http://dx.doi.org/10.3389/fphar.2018.00643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019484/
https://www.ncbi.nlm.nih.gov/pubmed/29973877
http://dx.doi.org/10.3389/fphar.2018.00643

Ejemplares similares